Novel evaluation of pulmonary hypertension associated with chronic lung disease using perfusion SPECT/CT: A pilot study.
perfusion imaging
phosphodiesterase 5 inhibitors
pulmonary hypertension
single‐photon emission computed tomography/computed tomography
vasodilator agents
Journal
Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
30
03
2024
revised:
26
06
2024
accepted:
19
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from pulmonary vasodilators is a significant clinical challenge because the presence of PH is associated with poorer survival. This study evaluated the severity of pulmonary circulation impairment in patients with CLD-PH using pulmonary perfusion single-photon emission computed tomography/computed tomography (SPECT/CT). This single-center, observational study enrolled patients with CLD-PH who had a mean pulmonary arterial pressure (PAP) ≥ 25 mmHg, as confirmed by right heart catheterization. The primary outcome was to measure the percentage of pulmonary perfusion defect (%PPD), calculated by dividing the perfusion defect volume from perfusion SPECT images by the lung volume from CT scan images. The secondary outcome was to assess the correlation between %PPD and baseline characteristics. The median %PPD was 52.4% (interquartile range, 42.5%-72.3%) in 22 patients. In multivariate linear regression analysis, both forced vital capacity (
Identifiants
pubmed: 39170759
doi: 10.1002/pul2.12423
pii: PUL212423
pmc: PMC11337537
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12423Informations de copyright
© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
Déclaration de conflit d'intérêts
Hiroshi Kimura worked in an endowment department supported by an unrestricted grant to Nippon Medical School from Actelion Pharmaceuticals Japan. The remaining authors declare no conflict of interest.